Mari Yoshida

Prof. Dr. Mari Yoshida

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2007 in Neuropathology
Verified
Journal Article
Closed access
PDF file
MYMari Yoshida
Mari Yoshida

13 June 2022 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
SKShunsuke Koga
Shunsuke Koga
KJKeith A. Josephs
Keith A. Josephs
IAIkuko Aiba
Ikuko Aiba
MYMari Yoshida
Mari Yoshida
DDDennis W Dickson
Dennis W Dickson
Corticobasal syndrome (CBS) is a clinical syndrome characterised by progressive asymmetric limb rigidity and apraxia with dystonia, myoclonus, cortical sensory loss and alien limb phenomenon. Corticobasal degeneration (CBD) is one of the most common underlying pathologies of CBS, but other disorders, such as progressive supranuclear palsy (PSP), Alzheimer’s disease (AD) and frontotemporal lobar degeneration with TDP-43 inclusions, are also associated with this syndrome.In this review, we describe common and rare neuropathological findings in CBS, including tauopathies, synucleinopathies, TDP-43 proteinopathies, fused in sarcoma proteinopathy, prion disease (Creutzfeldt-Jakob disease) and cerebrovascular disease, based on a narrative review of the literature and clinicopathological studies from two brain banks. Genetic mutations associated with CBS, includingGRNandMAPT, are also reviewed. Clinicopathological studies on neurodegenerative disorders associated with CBS have shown that regardless of the underlying pathology, frontoparietal, as well as motor and premotor pathology is associated with CBS. Clinical features that can predict the underlying pathology of CBS remain unclear. Using AD-related biomarkers (ie, amyloid and tau positron emission tomography (PET) and fluid biomarkers), CBS caused by AD often can be differentiated from other causes of CBS. Tau PET may help distinguish AD from other tauopathies and non-tauopathies, but it remains challenging to differentiate non-AD tauopathies, especially PSP and CBD. Although the current clinical diagnostic criteria for CBS have suboptimal sensitivity and specificity, emerging biomarkers hold promise for future improvements in the diagnosis of underlying pathology in patients with CBS.


21 August 2017 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MKMariko Kuroda
Mariko Kuroda
RMRieko Muramatsu
Rieko Muramatsu
NMNoriko Maedera
Noriko Maedera
YKYoshihisa Koyama
Yoshihisa Koyama
MHMachika Hamaguchi
Machika Hamaguchi
TYToshihide Yamashita
Toshihide Yamashita
Demyelination in the central nervous system (CNS) leads to severe neurological deficits that can be partially reversed by spontaneous remyelination. Because the CNS is isolated from the peripheral milieu by the blood-brain barrier, remyelination is thought to be controlled by the CNS microenvironment. However, in this work we found that factors derived from peripheral tissue leak into the CNS after injury and promote remyelination in a murine model of toxin-induced demyelination. Mechanistically, leakage of circulating fibroblast growth factor 21 (FGF21), which is predominantly expressed by the pancreas, drives proliferation of oligodendrocyte precursor cells (OPCs) through interactions with β-klotho, an essential coreceptor of FGF21. We further confirmed that human OPCs expressed β-klotho and proliferated in response to FGF21 in vitro. Vascular barrier disruption is a common feature of many CNS disorders; thus, our findings reveal a potentially important role for the peripheral milieu in promoting CNS regeneration.


26 February 2004 in Neuropathology
Verified
Journal Article
Closed access
PDF file
MYMari Yoshida
Mari Yoshida